In June 2019, Monopar signed a collaboration agreement with Grupo Español de Investigación en Sarcomas (GEIS) to develop camsirubicin in patients with advanced soft tissue sarcoma (ASTS). GEIS is an internationally renowned non-profit organization focused on the research and development of drugs for sarcomas. GEIS will be conducting a multi-country, randomized (1:1), open-label Phase 2 clinical trial evaluating camsirubicin head-to-head against doxorubicin in the 1st line setting, in patients with ASTS. Enrollment for the trial is anticipated to begin in early-2021 and will include approximately 170 ASTS patients. The primary endpoint of the trial will be progression-free survival, with secondary endpoints that will include response rate and overall survival. Camsirubicin has been granted Orphan Drug Designation in both the U.S. and EU.

Orphan Drug Designation

Learn more about the European Commission’s Orphan Drug Designation of camsirubicin for the treatment of soft tissue sarcoma

Orphan Drug Designation